[{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"e264a041-42a7-43c6-8cea-b309a736c283","acronym":"","url":"https://clinicaltrials.gov/study/NCT05101564","created_at":"2021-11-01T11:52:59.476Z","updated_at":"2024-07-02T16:35:06.853Z","phase":"Phase 2","brief_title":"Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer","source_id_and_acronym":"NCT05101564","lead_sponsor":"Stanford University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant • Truseltiq (infigratinib) • letrozole • zotatifin (eFT226) • amcenestrant (SAR439859) • Soltamox (tamoxifen citrate)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 03/20/2023","start_date":" 03/20/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-04-30"},{"id":"0c9cde18-3a26-4ee3-98a4-e047e06c19c6","acronym":"AMEERA-3","url":"https://clinicaltrials.gov/study/NCT04059484","created_at":"2021-01-18T19:53:51.259Z","updated_at":"2024-07-02T16:35:07.788Z","phase":"Phase 2","brief_title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","source_id_and_acronym":"NCT04059484 - AMEERA-3","lead_sponsor":"Sanofi","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • letrozole • anastrozole • exemestane • amcenestrant (SAR439859)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 367","initiation":"Initiation: 10/22/2019","start_date":" 10/22/2019","primary_txt":" Primary completion: 02/15/2022","primary_completion_date":" 02/15/2022","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-04-24"},{"id":"3d52136b-093e-4fc2-909c-ca05ccae6194","acronym":"AMEERA-1","url":"https://clinicaltrials.gov/study/NCT03284957","created_at":"2021-01-17T17:21:55.566Z","updated_at":"2024-07-02T16:35:19.757Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer","source_id_and_acronym":"NCT03284957 - AMEERA-1","lead_sponsor":"Sanofi","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • everolimus • Piqray (alpelisib) • Verzenio (abemaciclib) • amcenestrant (SAR439859) • midazolam hydrochloride"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 12/29/2027","primary_completion_date":" 12/29/2027","study_txt":" Completion: 12/29/2027","study_completion_date":" 12/29/2027","last_update_posted":"2024-02-12"},{"id":"6e2b640a-22f7-4b61-83cc-eeec6b4ab424","acronym":"AMEERA-2","url":"https://clinicaltrials.gov/study/NCT03816839","created_at":"2021-01-18T18:51:30.299Z","updated_at":"2024-07-02T16:35:25.014Z","phase":"Phase 1","brief_title":"Evaluation of Orally Administered Amcenestrant (SAR439859) in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)","source_id_and_acronym":"NCT03816839 - AMEERA-2","lead_sponsor":"Sanofi","biomarkers":" HER-2 • ER","pipe":"","alterations":" ","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e amcenestrant (SAR439859)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/25/2019","start_date":" 03/25/2019","primary_txt":" Primary completion: 10/27/2020","primary_completion_date":" 10/27/2020","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2023-12-28"}]